Semaglutide and cardiovascular outcomes in pts with type 2 diabetes

1. What is the leading cause of death and complications in patients with type 2 diabetes.

2. How many patients were enrolled in the SUSTAIN-6 trial?

3. What was the duration of the SUSTAIN-6 trial?

4. Which of the following was the primary composite outcome in the SUSTAIN-6 trial?

5.  Which of the following describes the patients included in the SUSTAIN-6 trial?

6. Which of the following was reported regarding death from cardiovascular causes?

7. Which of the following was reported regarding new or worsening nephropathy?

8. Which of the following adverse events occurred more frequently with semaglutide than with placebo?

9. What was the main reason for the higher rate of treatment discontinuation due to adverse events in the semaglutide group?

10. Which statement best reflects the conclusion of the SUSTAIN-6 trial?